HDAC1在肺癌中的潜在作用机制及研究进展OA

Lung cancer is the malignant tumor with the highest incidence and mortality rate worldwide.The current treatment methods have limited efficacy,and the prognosis of patients is poor.There is an urgent need to explore new therapeutic targets and strategies.Epigenetic modification disorders are closely related to the occurrence and development of tumors.Among them,histone deacetylase 1(HDAC1),as a key epigenetic regulatory molecule,participates in the regulation of biological pro-cesses such as cell proliferation,differentiation,and apoptosis.HDAC1 is highly expressed in lung cancer,and its expression level is closely related to the malignancy degree,clinical stage,and poor prognosis of lung cancer.Abnormal activation of HDAC1 is also one of the core factors for the resistance of lung cancer to chemotherapy,targeted therapy,and immunotherapy.The development of HDAC1 inhibitors provides a new direction for the treatment of lung cancer,and the combination with chemotherapy,targeted therapy,and immunotherapy can significantly enhance the synergistic anti-tumor effect.This article systematically reviews the structural characteristics and physiological functions of HDAC1,deeply explores its regulatory mechanism in lung cancer,elabo-rates on its association with lung cancer resistance,and summarizes the research and development progress,clinical trial status,and challenges of HDAC1 inhibitors,with the aim of providing new ideas for the precise treatment of lung cancer.